Empagliflozin is not only able to decrease blood glucose, but also can be used to
treat heart failure (HF).
1
,2
Clinical studies suggested that empagliflozin 25 mg is superior to 10 mg for patients
with HF with reduced ejection fraction (HFrEF).
3
,4
However, it was unclear if there are differences in the impacts of 10mg and 25mg
of empagliflozin on the outcomes of patients with HF with preserved ejection fraction
(HFpEF). The aim of this study was to compare the efficacy of different doses of empagliflozin
in HFpEF.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Canadian Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.N Engl J Med. 2020; 383: 1413-1424
- Empagliflozin in Heart Failure with a Preserved Ejection Fraction.N Engl J Med. 2021; 385: 1451-1461
- Comparison of 10 mg and 25 mg of Empagliflozin in Patients With Heart Failure With Reduced Ejection Fraction.Can J Cardiol. 2022; 38: 1641-1642
- Different Doses of Empagliflozin in Patients with Heart Failure with Reduced Ejection Fraction.Int Heart J. 2022; 63: 852-856
Article info
Publication history
Accepted:
January 20,
2023
Received in revised form:
January 19,
2023
Received:
January 3,
2023
Publication stage
In Press Journal Pre-ProofFootnotes
Funding Sources: None.
Disclosures: The authors had no conflicts of interest to disclose.
Identification
Copyright
© 2023 Published by Elsevier Inc. on behalf of the Canadian Cardiovascular Society.
